Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC vs. AbbVie Pay-For-Delay Suit Crafted For Supreme Court’s ‘Red Flag’ Test

This article was originally published in The Pink Sheet Daily

Executive Summary

But for the first time ever, Federal Trade Commissioners were split on whether to bring such a case; newer members voted ‘no.’

You may also be interested in...

FTC Faces Uphill Battle In AndroGel Pay-For-Delay Suit

While the Federal Trade Commission won a court order requiring AbbVie to turn over documents in its AndroGel patent settlement the judge dismissed a big chunk of the agency’s complaint.

Teva Pay-For-Delay Plausible; Judge Finds Payments Exceed Litigation Costs

Focused on $300 million in payments Cephalon made to generic firms to settle Provigil patent suits, case is second to proceed to trial since Supreme Court’s Actavis decision.

Pay-For-Delay Deals Drop In FY 2013; 10 Settlements May Undergo Further Analysis

Of 145 brand-generic patent settlements in FY 2013, 29 contained both compensation to a generic manufacturer and a restriction on generic entry, down from 40 the previous year; compensation is uncertain in 10 additional deals.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts